Heart Failure and Cardiomyopathies
JACC March 12, 2019
Volume 73, Issue 9
IMPACT OF LESS INVASIVE VENTRICULAR ENHANCEMENT TM (LIVE TM) COMPARED TO OPTIMAL
MEDICAL THERAPY ON CARDIAC OUTPUT IN PATIENTS WITH HFREF - PRELIMINARY RESULTS OF
A 12-MONTH MULTI-CENTER CMR TRIAL
Poster Hall, Hall F
Saturday, March 16, 2019, 3:45 p.m.-4:30 p.m.
Session Title: Heart Failure and Cardiomyopathies: Therapy 2
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1187-512
Authors: Felix Hennig, Lukas Stoiber, Tomas Lapinskas, Seyedeh Mahsa Zamani, Christoph Klein, Christoph Schmitz, Christoph Knosalla,
Lon Annest, David Schickling, Volkmar Falk, Burkert Pieske, Sebastian Kelle, German Heart Institute Berlin, Berlin, Germany, Charité
University Medicine Berlin, Berlin, Germany
Background: The Less Invasive Ventricular Enhancement (LIVETM, Bioventrix Inc.) technique with the Revivent TC™ system provides a
new hybrid, off-pump, catheter-based approach to improve symptoms in HFrEF patients with myocardial scarring (akinesia/dyskinesia)
and dilated left ventricles. AIm of the study was to assess the impact of the LIVETM technique vs. optimal medical therapy (OMT) on left
ventricular (LV) cardiac output at 12 months post-procedure.
Methods: We analyzed data of 40 HFrEF-patients enrolled in a multicenter trial. The LV cardiac output was assessed with the Revivent
TC™ in 20 patients, while 20 matched control group participants received OMT only. A standardized CMR protocol was performed at
baseline and at 12-month follow up in both groups.
Results: LVEF improved significantly by 48% in Revivent patients (23.3 ± 9.8 % vs. 34.6 ± 10.3 %; p < 0.001), but had not changed in
controls (33.0 ± 8.9 % vs 35.2 ± 7.8 %; p = 0.383) at 1-year follow up. Regarding LV cardiac output (median), a borderline significant
increase by ~ 8% was seen in the surgical group (CO: 4.6 ± 2.0 l/min vs. 5.3 ± 1.9 l/min; p = 0.06 but rather a decrease by ~ 10 % in the
control group (CO: 5.3 ± 2.1 l/min vs. 4.8 ± 1.5 l/min; p = 0.238) (Figure).
Conclusion: We demonstrate a significant improvement in LV function by 48% and an increase in cardiac output by around 8% 1 year after
using the Bioventrix Revivent TCTM. Our results suggest benefits for outcome in symptomatic HFrEF patients with myocardial scarring and
large ventricles compared to OMT.